

other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

**Authority:** 42 U.S.C. 653A(b)(1)(A) and (B); 42 U.S.C. 653A(g)(2)(A) and (B), 42 U.S.C. 503(h)(1)(A); and 26 U.S.C. 3304(a)(16)(B).

**Mary C. Jones,**  
ACF/OPRE Certifying Officer.

[FR Doc. 2025-07708 Filed 5-2-25; 8:45 am]

**BILLING CODE 4184-41-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2024-N-5890]

#### Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Generic Drug User Fee Program

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

**DATES:** Submit written comments (including recommendations) on the collection of information by June 4, 2025.

**ADDRESSES:** To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to <https://www.reginfo.gov/public/do/PRAMain>. Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910-0727. Also include the FDA docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:** Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733, [PRAStaff@fda.hhs.gov](mailto:PRAStaff@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

### Generic Drug User Fee Program

#### OMB Control Number 0910-0727—Revision

This information collection helps support implementation of FDA's Generic Drug User Fee Program (GDUFA), most recently reauthorized September 30, 2022. It includes information collections discussed in the document, “GDUFA Reauthorization Performance Goals And Program Enhancements Fiscal Years 2023–2027,” commonly referred to as the “Goals Letter” or “Commitment Letter.” The Commitment Letter represents the product of FDA discussions with the regulated industry and public stakeholders, as mandated by Congress. The Goals Letter identifies current GDUFA program objectives and general procedures for communicating with FDA. Agency guidance, as outlined in the Goals Letter, are utilized in the information collection. All Agency guidance documents are issued consistent with our Good Guidance Practice regulations (21 CFR 10.115), which provide for public comment at any time, as well as regulatory authority found in 21 CFR 314.445 (Guidance documents), currently approved in OMB control number 0910-0001.

The information collection also includes Form FDA 3974, the Generic Drug User Fee Cover Sheet and associated instructions, available for download at [https://userfees.fda.gov/OA\\_HTML/GDUFAfacilityCScreation.pdf](https://userfees.fda.gov/OA_HTML/GDUFAfacilityCScreation.pdf). Form FDA 3974 is used to provide a uniform format for the submission of information necessary to account for and track user fees, and to determine the amount of the fee required.

As we communicate on our website, potential applicants are encouraged to contact the FDA Generic Drugs Program with questions at any point in their development and application preparation processes. We have revised the information collection to include the submission of “controlled correspondence” within the scope of activity, including covered product authorizations (CPAs) provided for under the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (CREATE Act) (Pub. L. 116-94). Historically, and under the terms of the GDUFA, a controlled correspondence may be submitted by or on behalf of a generic drug manufacturer or related industry prior to submitting an abbreviated new drug application (ANDA). To provide respondents with assistance regarding the submission of controlled correspondence, we continue to develop and issue topic-specific

Agency guidance, including the following documents:

- Controlled Correspondence Related to Generic Drug Development (Controlled Correspondence Guidance) (<https://www.fda.gov/media/164111/download>, March 2024).

- Product-Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA (<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-specific-guidance-meetings-between-fda-and-anda-applicants-under-gdufa>, February 2023).

- Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA (<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-meetings-between-fda-and-anda-applicants-complex-products-under-gdufa-guidance-industry>, October 2022).

- Competitive Generic Therapies Guidance (<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/competitive-generic-therapies>, October 2022).

- Cover Letter Attachments for Controlled Correspondences and ANDA Submissions (<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cover-letter-attachments-controlled-correspondences-and-anda-submissions>, June 2023).

- How to Obtain Covered Product Authorization (<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-obtain-covered-product-authorization>, September 2022).

Each guidance document may be downloaded from our website where we maintain a searchable database at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>.

In the **Federal Register** of January 14, 2025 (90 FR 3225), we published a 60-day notice soliciting comment on the proposed collection of information. Two comments were received, one pertaining to product pricing and the other pertaining to plant-based ingredients. FDA appreciates these public comments; however, neither is responsive to the four information collection topics solicited under 5 CFR 1320.8(d) and therefore not discussed in this notice. We have made no adjustments in our estimated burden in response to the public comment.

We estimate the burden of this collection of information as follows:

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN<sup>1</sup>

Information collection; activity	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
Submission of Generic Drug User Fee Cover Sheet .....	500	7.616	3,808	0.5 (30 minutes) ...	1,904
	400	12.5	5,000	5 .....	25,000
<b>Total</b> .....	.....	.....	<b>8,808</b>	.....	<b>26,904</b>

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

Our estimate is based on available Agency data. Our burden estimate reflects an overall increase attributable to the inclusion of controlled correspondence and new generic drug product CPA requests.

Dated: April 24, 2025.

**Grace R. Graham,**  
Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2025-07759 Filed 5-2-25; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket Nos. FDA-2024-D-3067; FDA-2024-D-3863]

### Recommendations To Reduce the Risk of Transmission of Disease Agents Associated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Recommendations To Reduce the Risk of Transmission of *Mycobacterium Tuberculosis* by Human Cells, Tissues, and Cellular and Tissue-Based Products; Draft Guidances for Industry; Availability

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of availability.

**SUMMARY:** The Food and Drug Administration (FDA or the Agency) is withdrawing two final guidances entitled “Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)” and “Recommendations to Reduce the Risk of Transmission of *Mycobacterium Tuberculosis* (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)” and reissuing them as draft guidances.

**DATES:** Submit either electronic or written comments on the draft guidances by July 7, 2025 to ensure that the Agency considers your comment on

the draft guidances before it begins work on the final version of the guidances.

**ADDRESSES:** You may submit either electronic or written comments on Agency guidances at any time as follows:

#### *Electronic Submissions*

Submit electronic comments in the following way:

- *Federal eRulemaking Portal:* <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

#### *Written/Paper Submissions*

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

**Instructions:** All submissions received must include the Docket No. FDA-

2024-D-3067 for “Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)” or the Docket No. FDA-2024-D-3863 for “Recommendations to Reduce the Risk of Transmission of *Mycobacterium Tuberculosis* (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps),” as appropriate. Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.

- **Confidential Submissions**—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.